10,198 Results

FDA issues Complete Response Letter for Zynquista to treat type 1 diabetes

 Added 2 days ago

The FDA has issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista (sotagliflozin)...

Oral semaglutide compared to Januvia in patients with type 2 diabetes

 Added 2 days ago

Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia (sitagliptin 100 mg)...

FDA issues Complete Response Letter to Recro Pharma relating to IV meloxicam

 Added 2 days ago

Recro Pharma, Inc. announced it has received a second Complete Response Letter (CRL) from the FDA Office of Drug Evaluation...

Phase III extension study Recorlev meets objectives in Cushing’s syndrome

 Added 3 days ago

Strongbridge Biopharma announced the top-line findings from the extended evaluation phase of the pivotal Phase III SONICS study of Recorlev...

BD issues statement on FDA relating to paclitaxel-coated devices and long term mortality

 Added 3 days ago

BD (Becton, Dickinson and Company) issued the following statement related to the recent letter from FDA to health care providers...

Phase III (Clarity AD/Study 301) of BAN 2401 is initiated for early Alzheimer's disease

 Added 3 days ago

Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN 2401, an anti-amyloid beta...

ILC 2019 | Find out more

 Added 4 days ago

ILC 2019 | Find out more

View details from the International Liver Congress which takes place in Vienna, Austria from 10th - 14th April 2019.

ELCC 2019 Preview

 Added 4 days ago

ELCC 2019 Preview

View details from the European Lung Cancer Congress (ELCC 2019) which takes place in Geneva, Switzerland from 10th - 13th April 2019.

European Association of Urology Conference 2019 - Highlights and Insights

 Added 4 days ago

European Association of Urology Conference 2019 - Highlights and Insights

Didn't make it to EAU19? Here's a round up of some of the key takeaways, presented at the 34th European Association of Urology conference held in Barcelona in March. 

Testosterone slows prostate cancer recurrence in low-risk patients

 Added 4 days ago

US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients.

Load more